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Natural killer (NK) cells are a noteworthy lymphocyte subset in cancer adoptive cell
therapy. NK cells initiate innate immune responses against infections and malignancies
with natural cytotoxicity, which is independent of foreign antigen recognition. Based
on these substantive features, genetically modifying NK cells is among the prime
goals in immunotherapy but is currently difficult to achieve. Recently, we reported a
fully human CAR19 construct (huCAR19) with remarkable function in gene-modified
T-cells. Here, we show efficient and stable gene delivery of huCAR19 to primary human
NK cells using lentiviral vectors with transduction efficiencies comparable to those
achieved with NK cell lines. These huCAR19 NK cells display specific and potent
cytotoxic activity against target cells. To improve homing of NK cells to the bone
marrow, we augmented huCAR19 NK cells with the human CXCR4 gene, resulting in
transgenically augmented CAR NK cells (TRACKs). Compared to conventional CAR NK
cells, TRACKs exhibit enhanced migration capacity in response to recombinant SDF-
1 or bone marrow stromal cells while retaining functional and cytolytic activity against
target cells. Based on these promising findings, TRACKs may become a novel candidate
for immunotherapeutic strategies in clinical applications.
Keywords: natural killer cell, chimeric antigen receptor, immunotherapy, fully human CAR, CD19, huCAR19,
transgenically augmented CAR NK cell, chemokine receptor 4
INTRODUCTION
Cancer immunotherapy using CD19-specific chimeric antigen receptor (CAR) modified T-cells
(CAR T-cells) has shown remarkable clinical benefit in patients with relapsed or refractory B-cell
malignancies. The first CAR T-cell products, tisagenlecleucel (Kymriah, Novartis) and axicabtagene
ciloleucel (Yescarta, Gilead), were approved in the United States in 2017 and Europe in 2018.
However, so far, this success has not been translated to other hematological indications, such as
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acute myeloid leukemia (AML) or even solid tumors. In addition,
CAR T-cell therapies can be associated with severe, sometimes
even life-threatening adverse events, such as cytokine release
syndrome (CRS), neurotoxicity, B-cell aplasia, and/or graft-
versus-host disease (GvHD) (1).
Another immune cell type that can recognize and destroy
cancer cells is natural killer (NK) cells. Matching their name,
this small subset of lymphocytes initiates the innate immune
response against infections and malignancies with its natural
cytotoxicity behavior in hand. NK cells rely on germline encoded
inhibitory and activating receptors sensing a misbalance of
the corresponding ligands on the target cell surface and are,
therefore, independent of foreign antigen recognition. In recent
years, NK cell–based immunotherapy approaches have been
developed for the treatment of various malignancies in both
autologous and allogeneic settings. The transfer of ex vivo
expanded autologous and allogeneic NK cells has been found to
be safe and well tolerated in a range of clinical trials with no
signs of GvHD, CRS, or neurotoxicity, but the effect on tumor
suppression appears to be low for autologous NK cell infusions
or highly dependent on the type of cancer for allogeneic NK cell
infusions (2).
Similar to T-cells, NK cells can be genetically modified
with CAR genes to improve their antitumor potential. CAR
expression on the surface of NK cells mimics an activating
receptor providing a strong activation signal upon contact with
its respective ligand on the tumor cell, resulting in CAR NK
cell activation and target cell lysis. Considering the beneficial
safety profile of NK cells and the possibility to use them as
an “off-the-shelf ” product in an allogeneic setting make CAR
NK cells an attractive alternative to CAR T-cells. However,
compared to T-cells, NK cells are harder to modify with viral
vectors due to their intrinsic antiviral defense mechanisms
(3). Transduction efficiencies of NK cells vary tremendously
depending on the cell source, the viral vector system, and
the transduction enhancer used (4). Lentiviral vectors (LVs)
pseudotyped with the glycoprotein of the vesicular stomatitis
virus (VSV-G) are classically used to generate CAR T-cells but
are less efficient for NK cells with transduction efficiencies of 20–
40% (5, 6). Therefore, optimization of gene transfer protocols for
VSV-G pseudotyped LV for the generation of CAR NK cells is
urgently required.
Today, fewer than 15 clinical trials using CAR NK cells are
performed worldwide, which is far below the amount of ongoing
CAR T-cell trials (>200) (1, 7). Similar to CAR T-cell trials, most
CAR NK cell trials use a CD19-specific CAR molecule derived
from the murine antibody FMC63 (8, 9). Due to the potential
of murine-derived targeting domains causing anaphylaxis, more
and more CAR T-cell studies are investigating humanized or
fully human CAR constructs (1). In this respect, recently, fully
human CD19-specific and fully human mesothelin-specific CAR
constructs were reported showing efficient expression and strong
antitumor activity in T-cells (10–13). Because murine-derived
CAR molecules possess the same risk of causing anaphylaxis
in engineered CAR NK cells, CAR NK cell approaches should
evaluate the feasibility of humanized or fully human CAR
constructs as well.
Persistent tumor cells in the bone marrow are a major cause
of cancer relapse in several indications including AML (14–
16). Trafficking of NK cells to and from the bone marrow
essentially depends on chemotaxis. NK cells basically complete
their maturation steps in the bone marrow, are retained
there, or egress to and emerge in the blood circulation (17).
Retention of NK cells in the bone marrow is primarily
driven by the interaction of the CXCR4 chemokine receptor
expressed on NK cells and its ligands SIP5 (sphingosine-
1 phosphate receptor 5) and CXCL12, also known as SDF-
1 (stromal cell–derived factor 1), abundantly represented
by bone marrow stromal cells. During NK cell maturation,
CXCR4 expression decreases, promoting NK cell release from
the bone marrow (18). It has been shown that NK cell
chemotaxis to the bone marrow is induced by SDF-1 and
can be prevented utilizing AMD3100, a CXCR4 antagonist
(Plerixafor), resulting in an increase of NK cells in the spleen
and other peripheral organs (17, 18). In this respect, it was
recently demonstrated that the expression of CXCR4 in NK
cells can improve their homing to the bone marrow (19).
Combined expression of CAR and CXCR4 might, therefore,
enable enhanced chemotaxis of CAR NK cells to the bone marrow
allowing more efficient targeting of persistent tumor cells in the
tumor niche environment.
To our knowledge, we report here for the first time
the highly efficient transduction of primary NK cells with
VSV-G pseudotyped LVs delivering a fully human, CD19-
specific CAR construct (huCAR19). Generated huCAR19 NK
cells are shown to exhibit strong and specific antitumor
activity. To augment homing to the bone marrow, NK
cells were modified to express human CXCR4 in addition
to the huCAR19 construct. These transgenically augmented
CAR NK cells (TRACKs) are proven to overexpress CXCR4,
which leads to enhanced chemotaxis toward SDF-1 and bone




This research was approved by the Ethics Committee of the
University Hospital Frankfurt, Germany. Written informed
consent was obtained from each donor.
Cell Lines and Primary Cells
HEK-293T (ATCC CRL-11268) and HT1080 (ATCC CCL-121)
cells were grown in Dulbecco’s modified Eagle’s medium (DMEM;
Biowest, Nuaillé, France) supplemented with 10% fetal calf
serum (FCS; Biochrom, Berlin, Germany) and 2 mM L-glutamine
(Sigma-Aldrich, Munich, Germany). Nalm-6 [peripheral blood
derived B cell precursor leukemia cells (ALL), CD19+], JeKo
[peripheral blood derived B cell lymphoma cells (non-Hodgkins
lymphoma), CD19+], CD19-negative JeKo (CD19negJeKo), SUP-
B15 [bone marrow derived B cell precursor leukemia cells
(ALL), CD19+], and BV-173 [peripheral blood derived B cell
precursor leukemia cells (chronic myeloid leukemia), CD19+]
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cell lines were grown in RPMI 1640 (Biowest, Nuaillé, France)
supplemented with 10% FCS and 2 mM L-glutamine. NK92,
a malignant non-Hodgkins lymphoma cell line (ATCC R© CRL-
2407), and NKL, a large granulocyte leukemia cell line (20), were
cultivated in X-Vivo 10 medium (Lonza, Belgium) supplemented
with 5% human serum (Sigma, United States) and 100 IU/ml
of IL-2 (Miltenyi Biotec, Bergisch-Gladbach, Germany). All cell
lines were cultivated at 37◦C, 5% CO2, and 95% humidity for
up to 1 month. Cells were split every 2 to 3 days and did not
undergo more than 20 passages. Regular testing for Mycoplasma
was performed for all cell lines using a PCR Mycoplasma Test Kit
(PanReacApplichem, Germany).
Human PBMCs were isolated from the fresh blood of
healthy anonymous donors or buffy coats purchased from the
German blood donation center (DRK-Blutspendedienst Hessen,
Frankfurt, Germany). Primary NK cells were purified by negative
selection using the NK cell isolation kit according to the
manufacturer’s instructions (Miltenyi Biotec, Bergisch-Gladbach,
Germany). After NK cell isolation, 2 × 106 cells were cultivated
per well in a 24-well plate in 400 µl of X-Vivo 10 (Lonza,
Belgium) medium supplemented with 5% human serum (Sigma,
United States) and 100 IU/ml of IL-2 (Miltenyi Biotec, Bergisch-
Gladbach, Germany) for at least 72 h at 37◦C. The purity
of NK cells after isolation was determined by flow cytometry
(Supplementary Figures S1B,C).
Transgene Constructs
The fully human anti-CD19-CAR construct (kindly provided
by Dr. Brian G. Till, Fred Hutchinson Cancer Research Center,
Seattle, WA, United States) was previously described (11). In
brief, the huCAR19 construct consists of the encoding sequences
of the VL and VH region of the human 21 Da antibody
linked by a 16 amino acid peptides followed by a hinge
domain derived from human CD8a, the transmembrane and
costimulatory domain of human 4-1BB and the signaling domain
of CD3ζ. For the generation of the huCAR19.CXCR4 construct,
the human CXCR4 coding sequence was cloned downstream to
the huCAR19 sequence linked via self-cleaving peptide P2A. Both
constructs reside in the clinical grade lentiviral expression vector
SINpWPT (21) and are under the control of a human elongation
factor-1 alpha (EF1α ) promoter.
Lentiviral Vector Generation,
Concentration, and Titration
Vector particles were generated by transient transfection of
HEK-293T cells using polyethylenimine (PEI; Sigma-Aldrich,
Munich, Germany) and third-generation packaging plasmids as
described before (22–24). In brief, 1 day before transfection, 1.5-
2 × 107 cells were seeded into a T175 flask. In total, 35 µg DNA
was added to 2.3 ml of DMEM without additives and combined
with 2.2 ml DMEM containing 140 µl of 18 mM PEI solution.
The transfection solution was mixed and incubated for 20 min at
room temperature. The culture medium was exchanged to 10 ml
DMEM supplemented with 15% FCS and 2 mM L-glutamine
before the transfection solution was added to HEK-293T cells.
4–6 h later, the medium was replaced by DMEM supplemented
with 10% FCS and 2 mM L-glutamine. 2 days after transfection,
the cell culture supernatant was collected, filtered via a 0.45 µm
filter, and released vector particles were concentrated by a 20%
sucrose cushion at 4500 × g for 24 h. The supernatant was
discarded, and pellets were resuspended in 60 µl Dulbecco’s
Phosphate Buffered Saline (PBS; Lonza, Cologne, Germany) per
T175 flask. A third-generation lentiviral packaging system was
used to produce CAR-carrying lentiviral particles. Plasmid ratios
for the generation of lentiviral particles were described previously
(22) and can be found in the Supplementary Table S1.
All produced vector particles were titrated by transducing
HT1080 cells with five serial dilutions of vector particles.
The expression of huCAR19 transgene was detected 4 days
post-transduction by flow cytometry. Titers were calculated as
described before (25). Particle numbers were determined using
Nano sight NS300 (Malvern Ltd., United Kingdom).
NK Cell Transduction
For transduction of NK cell lines, 3 × 104 of NK-92 or NKL
cells were seeded into a single well of a 96-well flat-bottom plate
in 100 µl X-Vivio10 medium supplemented with 5% human
serum and 100 IU/ml IL-2 (complete X-Vivo medium). The
transduction enhancer polybrene (Sigma) was added to the cells
at a concentration of 8 µg/ml before adding 100 µl complete
X-Vivo 10 medium containing 2 µl of concentrated vector stock.
For transduction of primary NK cells, 4 × 104 purified
NK cells, if not otherwise specified, were seeded into a
single well of a 96-well flat-bottom plate in 100 µl complete
X-Vivo 10 medium 72 h post NK cell isolation. For each
transduction experiment, 2 µl of concentrated vector stock
was used. The transduction enhancer polybrene (Sigma-Aldrich,
Germany) was utilized at a concentration of 8 µg/ml and
added directly to the cells prior to transduction. Vectofusin-
1 (Miltenyi Biotec, Germany) was used according to the
manufacturer’s instructions and, as described before (26), at
a final concentration of 10 µg/ml. In brief, Vectofusin-1 and
vector particles were diluted in X-Vivo10 medium without
additives in a total volume of 50 µl before both solutions
were mixed, incubated for 5–10 min at room temperature, and
finally added to the NK cells. Retronectin (Takara, United States)
was precoated in a 96-well flat-bottom plate at a concentration
of 20 µg/cm2 and incubated overnight at 37◦C 1 day before
transduction. Afterward, Retronectin solution was removed,
the plate was blocked with 2% BSA in PBS for 30 min and
washed with PBS before seeding NK cells and adding vector
particles. If not otherwise specified, polybrene was used as a
transduction enhancer.
To increase transduction efficiency, spinfection was
performed at 850 × g at 32◦C for 90 min. Afterward, NK
cells were gently resuspended by pipetting. Fresh complete
medium was added every other day after transduction until
cell analysis. Transgene expression was determined by flow
cytometry 3 days post-transduction. The functional capability of
transduced cells, including migration assay, cytotoxic activity,
cytokine production, and degranulation, was analyzed 4 days
after transduction. An overview of the experimental setup is
provided in Supplementary Figure S1A.
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Cytotoxicity Assay
Cytotoxic activity of huCAR19-LV or huCAR19.CXC4-LV
transduced NK cells was determined using CD19+ Nalm-6 cells
or other tumor cell lines. CAR expression was detected 72 h post-
transduction by flow cytometry, and cytotoxic activity of NK
cells was evaluated on the following day. 5 × 104, 2.5 × 104,
or 1 × 104 CAR-positive NK cells or untransduced NK cells
were cocultured with 1 × 104 Nalm-6 cells that were previously
labeled with CellTraceTM CFSE (Invitrogen, United States)
according to the manufacturer’s instructions. To compensate for
variations of transduction efficiency, the effector cell population
was normalized to an absolute NK cell number by the addition of
untransduced NK cells. Nalm-6 cells without effector cells were
used as control. Coculture was performed for 4 h at 37◦C and 5%
CO2 in a total volume of 200 µl RPMI medium supplemented
with 10% FCS and 2 mM L-glutamine. Afterward, the cell mixture
was stained for dead cells using the fixable viability dye eFluor
780 (Thermo Fisher Scientific, United States) according to the
manufacturer’s instructions and analyzed by flow cytometry. The
percentage of dead target cells was analyzed as the CFSE positive,
viability dye positive cell population.
Degranulation and IFNγ Secretion Assay
Four days after transduction, 2 × 104 CAR NK cells were
seeded in to a single well of 96-well V-bottom plates together
with 2 × 104 Nalm-6 cells in a total volume of 200 µl
RPMI medium supplemented with 10% FCS and 2 mM L-
glutamine and incubated at 37◦C and 5% CO2. Untransduced
NK cells were used as a control. The anti-CD107a antibody
(Biolegend, United States) was added directly after seeding the
cells, and a mixture of protein transport inhibitors containing
brefeldin A (BD Biosciences, United States), and monensim (BD
Biosciences) were added after 1 h of coculture according to
the manufacturer’s instruction, and cells were incubated for 3
additional hours. At the end of the coculture, supernatant and
cells were separately collected. To determine CD107a expression,
NK cells were stained for CD3, CD14, CD19, and CD56 markers
as well as for dead cells using fixable viability dye eFluor 506.
NK cell degranulation was determined by analyzing CD107a
expression as an NK cell degranulation marker on live, CD3−,
CD14−, CD19−, and CD56+ cells by flow cytometry. Collected
supernatants were stored at −80◦C and used to detect secreted
IFNγ by a Duoset ELISA kit (R&D systems, United States)
according to the manufacturer’s protocol.
Migration Assay
A migration assay utilizing polycarbonate transwell plates with
a 6.5 mm diameter and 5 µm pore size (Corning Costar,
United States) was used to assess the migration potential of NK
cells. 4 days after transduction, 1 × 105 NK cells were loaded
in the upper chamber in a total volume of 200 µl X-Vivo10
medium supplemented with 5% human serum and appropriate
cytokines. Untransduced NK cells cultured in parallel were used
as control. Next, 100 ng/ml of SDF-1 (CXCL12; SinoBiological,
United States) diluted in 200 µl X-Vivo10 medium supplemented
with 5% human serum (Sigma, United States) and 100 IU/ml
of IL-2 were added in the lower well. After 2 h of incubation
at 37◦C and 5% CO2, cells and medium of the lower chamber
were harvested, and the number of migrated cells was quantified
by flow cytometry analysis. To inhibit chemotaxis, 25 µg/ml
AMD3100 (CXCL12 antagonist; Sigma Aldrich, Germany) was
added to NK cells for 2 h at 37◦C prior to the experiment onset.
To evaluate the cytotoxic functionality of migrated cells, a
coculture assay of harvested NK cells with CD19+ Nalm-6 cells
was performed. For this purpose, migrated cells were collected,
counted, and cocultured with Nalm-6 cells at a 1:1 ratio for
4 h at 37◦C and 5% CO2, followed by washing and staining for
viability and CD19. The cytotoxic capacity of migrated NK cells
was determined by the decrease in the percentage of living CD19
positive cells analyzed by flow cytometry.
Furthermore, to simulate the migration of NK cells toward
the bone marrow niche, a migration assay with primary culture-
expanded bone marrow–derived mesenchymal stromal cells
(BMSCs) was performed. BMSCs were generated from pooled
bone marrow mononuclear cells and expanded to the end of
passage 3 as described (27). After thawing, cells were cultivated
for 5 days in basal medium containing 10% platelet lysate. 1 day
before starting the migration assay, 0.5× 105 BMSCs were seeded
in the lower chamber of a transwell plate. On the next day, the
medium was exchanged to 200 µl X-Vivo10 medium without any
supplement. Transduced and untransduced NK cells were labeled
with CellTraceTM CFSE (Invitrogen, United States) according
to the manufacturer’s instructions, and 1 × 105 CSFE-labeled
NK cells with or without AMD3100 treatment were loaded into
the upper chambers of the transwell. After 2 h of incubation,
microscopic pictures from the lower chamber were acquired
(Zeiss AxioVert 200 Inverted Fluorescent Microscope, Germany;
power x10 magnification), and the number of migrated cells was
quantified by flow cytometry analysis.
Flow Cytometry
Flow cytometry analysis was performed using the MACSQuant R©
Analyzer 10 (Miltenyi Biotec, Bergisch-Gladbach, Germany),
and data were analyzed by FCS Express 6 (de novo Software,
Glendale, CA, United States). To determine the purity of NK
cell purification on the day of isolation, 72 h after culture, and
during the final analysis, cells were stained with fixable viability
dye eFluor506 (e.bioscience), anti-CD3 (clone BW264/56), anti-
CD14 (clone TÜK4), and anti-CD19 (clone LT19) antibodies
all conjugated with VioGreen as well as APC-labeled anti-CD56
antibody (all Miltenyi Biotec, Germany). Viable cells that were
CD3−, CD14−, and CD19 negative cells but positive for CD56
were considered to be NK cells according to the gating strategy
in Supplementary Figure S1B. CXCR4 was detected using anti-
CD184 (clone 12G5; BD Horizon, United States) conjugated to
BV421. CAR expression was determined by cell labeling with
biotinylated human recombinant CD19 protein (CD19-Fc, Acro
Biosystemms, United States) followed by secondary labeling
with PE-conjugated Streptavidin (Miltenyi Biotec, Germany).
FITC conjugated anti-CD107a (LAMP-1) antibody (Biolegend,
United States) was used to evaluate degranulation on NK cells
after coculture with target cells. After staining, cells were washed
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twice with washing buffer (PBS, 2% FCS, 0.1% NaN3) and fixed
with PBS containing 1% formaldehyde prior to analysis.
Statistical Analysis
Statistical analyses were performed with Prism 7 software
(GraphPad, San Diego, CA, United States). Statistical
significance was determined by applying the unpaired two-
tailed Student’s t test as indicated; p values less than 0.05 were
considered significant.
RESULTS
Efficient huCAR19 Gene Delivery to
Primary NK Cells
A fully human, second-generation CD19-specific CAR construct
(huCAR19) as well as the huCAR19 construct linked to the
human CXCR4 sequence via a P2A site (huCAR19.CXCR4) were
used to produce CAR NK cells by lentiviral transduction. The
huCAR19 gene cassette contains the scFv regions derived from
the human 21D antibody as a binding domain followed by a
CD8a hinge domain, the transmembrane, and the costimulatory
domain from 4-1BB as well as the intracellular signaling domain
of CD3ζ (Figure 1A). LVs encoding both CAR transgenes were
produced in several batches. Characteristics of produced LV
batches, including titer, particle count, and average size as well
as corresponding multiplicity of infection (MOI), are listed in
Supplementary Table S2.
First, CAR gene delivery to the NK cell lines NKL and NK-92
was analyzed by applying polybrene as a transduction enhancer,
revealing very efficient gene transfer (Figures 1B,C). 3 days
after transduction, nearly 100% of the NKL and NK-92 cells
were transduced by huCAR19-LV. Next, generated huCAR19-
LV particles were applied to transduce purified, primary NK
cells in parallel to NKL and NK-92 cells in the presence of
polybrene. Surprisingly, the transduction of primary NK cells
was as efficient as those of NK cell lines determined by CD19-
CAR detection 3 days after vector treatment (Figure 1C). On
average 94.4% of NKL, 99.1% of NK-92, and 96.2% of primary
NK cells were transduced. An overview of the experimental
timeline and gating strategy for primary NK cells is provided in
Supplementary Figure S1.
To investigate the effect of different transduction enhancers
on gene delivery to primary NK cells, transduction of NK
cells was performed in the presence or absence of polybrene,
Vectofusin-1, and Retronectin. The most pronounced gene
transfer was achieved in the presence of polybrene (nearly
90%) compared to Vectofusin-1 with 70.1% and Retronectin
with 30.4% (Figure 1D). Samples without any enhancer showed
a moderate transduction rate (5.4%). Therefore, all further
experiments were performed using polybrene as an enhancer.
In the next step, we investigated whether adding the human
CXCR4 gene sequence to the huCAR19 construct has any adverse
effect on huCAR19 expression. Nearly equivalent transduction
rates were achieved for both CAR constructs with a mean
transduction efficiency of 87.11% for huCAR19-LV and 85.25%
for huCAR19.CXCR4-LV (Figures 1E,F). Prolonged cultivation
up to 2 weeks post transduction revealed that the CAR constructs
were stably expressed on primary NK cells as determined by
flow cytometry (Supplementary Figure S2A). These results
demonstrate the feasibility of highly efficient CAR gene transfer
to primary NK cells by applying LV vectors.
CXCR4 Expression Can Be Increased on
Primary NK Cells Using
huCAR19.CXCR4-LV
To enhance the migration capability of CAR NK cells toward
tumor cells residing in the bone marrow, we generated
huCAR19.CXCR4-LV particles delivering CXCR4 in addition
to the CAR construct. To evaluate the ability of the vector to
induce CXCR4 overexpression, primary NK cells were isolated
from healthy donors and cultivated with IL-2 for 2 days
before transduction with huCAR19.CXCR4-LV or huCAR19-
LV particles. Prior to transduction, highly purified primary
NK cells were less than 17% CXCR4 positive (Supplementary
Figure S1C), and 72 h post-transduction, significant CXCR4
expression was detected on NK cells treated with LV particles
harboring the huCAR19.CXCR4 construct (on average, 81.5% in
the CD56+ cell population), and co-expression of both inserts
was observed (Figure 2). On average, more than 84% of the
cells co-expressed CAR and CXCR4 upon huCAR19.CXCR4
gene delivery (Figure 2B). In contrast, CXCR4 was only
expressed on 25.7% of CD56+ or 27.1% of huCAR19+
NK cells treated with huCAR19-LV particles (Figure 2).
Notably, the level of CXCR4 on NK cells transduced with
the huCAR19 construct alone was not significantly enhanced
and was similar to the levels of untransduced NK cells
cultivated in parallel (Figure 2A). Expression of CXCR4 was
stable for at least 2 weeks post-transduction as determined by
flow cytometry (Supplementary Figures S2B,C). Notably, cell
viability, proliferation capacity, and phenotype of the generated
CAR NK cells were comparable to untransduced primary NK
cells cultured in parallel, demonstrating that the transduction
process or transgene expression did not negatively affect NK cell
cultivation (Supplementary Figure S3).
Functional Evaluation of huCAR19
Modified NK Cells
In the next step, the specific cytolytic activity of huCAR19 NK
cells augmented with or without CXCR4 was tested. For this
purpose, CFSE-labeled CD19+ Nalm-6 cells were cocultured with
the genetically modified NK cells at a different effector to target
ratios for 4 h. In all experiments, at least 63% of the NK cells
were CAR positive (Supplementary Figure S4A). Both types
of huCAR19 NK cells efficiently killed the tumor cells in all
applied ratios (Figure 3A). Already at an effector-to-target ratio
of 2.5 to 1, nearly 80% of all tumor cells were lysed by the
genetically modified NK cells. In contrast, untransduced NK
cells showed only moderate cytotoxic activity against the CD19+
Nalm-6 cells (less than 20% dead cells for all tested effector-to-
target ratios; Figure 3A). To further demonstrate the specificity
of the huCAR19 NK cells, CD19 positive (SUP-B15, BV-173,
and JeKo) and negative (CD19negJeKo) tumor cell lines were
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FIGURE 1 | Fully human CAR gene delivery to NK cells. (A) Schematic illustration of huCAR19 (top) and huCAR19.CXCR4 (bottom) constructs used to generate
CAR NK cells. The second-generation fully human CAR consists of the anti-CD19 scFv derived from the human monoclonal antibody 21 Da (αCD19) linked to the
hinge domain of human CD8a (CD8 Hinge), the transmembrane and costimulatory domains of human 4-1BB (4-1BB TMD and 4-1BB), and the signaling domain of
CD3ζ. The coding sequence of human CXCR4 is connected to the CAR gene by a P2A self-cleaving peptide. Transgene expression is under control of the human
elongation factor 1-α promoter (EFI-α). (B,C) NK-92 and NKL cells as well as primary NK cells were transduced with huCAR19-LV particles in the presence of
polybrene and analyzed for CAR expression 3 days post-transduction by flow cytometry. The percentage of CD19-CAR-positive cells is indicated. Each transduction
experiment was performed at least five times. Representative dot plots for NK-92 and NKL-transduced cells are shown in B. Individual results of transduced NK-92,
NKL, and primary NK cells are shown in C as a bar diagram with mean value and SD. (D) Effect of different transduction enhancers on huCAR19 gene delivery to
primary NK cells; 3 × 104 primary NK cells were transduced with huCAR19-LV particles in the presence or absence of polybrene, Vectofusin-1, and Retronectin.
3 days post-transduction, huCAR19 transgene expression was detected by flow cytometry. Representative dot plots are shown (n = 2, with technical replicates). The
percentage of huCAR19-positive NK cells is indicated. (E,F) Addition of human CXCR4 sequence to the huCAR19 transgene did not impact huCAR19 expression.
Primary NK cells of six different donors were transduced with huCAR19-LV or huCAR19.CXCR4-LV particles in the presence of polybrene. The percentage of
CD19-CAR-positive cells was analyzed by flow cytometry 3 days post-transduction. Each transduction experiment was performed at least 10 times. Three to four
individually produced vector stocks were applied. Individual results as well as mean value, SD, and significance are shown in E. Representative dot plots are shown
in F. ns, not significant by unpaired t test (p = 0.5245).
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FIGURE 2 | CXCR4 overexpression on NK cells. Primary NK cells were transduced with huCAR19.CXCR4-LV or huCAR19-LV particles and analyzed for CXCR4
expression by flow cytometry 3 days post-transduction. Untransduced (unt) cells were cultured and analyzed in parallel. Each transduction experiment was
performed at least 10 times with technical replicates. Three to four individually produced vector stocks were used. Mean value, SD, and significance are indicated.
(A) Surface expression of CXCR4 on CD56-positive NK cells. Representative dot plots (upper panel) indicate the percentage of cells in each quadrant. Individual
results of each experiment for CD56, CXCR4-double positive cells are shown in the lower panel. (B) Surface expression of CXCR4 on CD19-CAR-positive NK cells.
Representative dot plots (upper panel) indicate the percentage of cells in each quadrant. Individual results of each experiment for CXCR4, CAR-double positive cells
are shown in the lower panel. ****p < 0.0001; ns, not significant by unpaired t test. Characteristics of isolated, primary NK cells prior to transduction are shown in
Supplementary Figure S1.
evaluated in a killing assay. SUP-B15, BV-173, and JeKo cells
were efficiently lysed by both types of the huCAR19 NK cells,
and only background killing was present for CD19negJeKo cells
or untransduced NK cells (Supplementary Figures S4B–E).
Subsequently, we investigated the activation-induced
degranulation and interferon gamma (IFNγ) secretion by the
TRACKs upon coincubation with CD19+ Nalm-6 cells at an
effector-to-target ratio of 1:1. Degranulation was measured
by surface detection of the degranulation marker CD107a
by flow cytometry and IFNγ secretion by ELISA of the
coculture supernatants. The average percentage of degranulation
marker after specific target stimulation was comparable for
huCAR19 and huCAR19.CXCR4 NK cells (on average, 51.5
and 49.9%, respectively) and significantly higher than CD107a
level in untransduced control cells (26.4%; Figure 3B and
Supplementary Figure S5). Similarly, IFNγ secreted by
huCAR19 and huCAR19.CXCR4 NK cells was significantly
higher upon coculture with tumor cells compared to unmodified
NK cells although no difference in IFNγ secretion was detected
between both CAR NK cell products (Figure 3C). Altogether,
these data show that both CAR NK cell products are functional
with regard to CAR-dependent specific tumor lysis.
huCAR19.CXCR4 NK Cells Display
Enhanced Chemotaxis Activity
Next, the ability of CXCR4 gene delivery to enhance NK
cell chemotaxis toward CXCL12 was addressed. Migration
of huCAR19.CXCR4 NK cells as well as of huCAR19 or
untransduced NK cells was determined in a transwell migration
assay. Chemotaxis of NK cells from the upper well toward the
chemotactic factor SDF-1 in the lower chamber was investigated
after 2 h by counting the amount of migrated NK cells.
For huCAR19.CXCR4 gene-modified NK cells, the number
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FIGURE 3 | Functional characteristics of gene-modified CAR NK cells. Analysis of cytotoxic function, degranulation, and IFNγ secretion of huCAR19 or
huCAR19.CXCR4 gene-modified primary NK cells upon cocultivation with CD19-positive Nalm-6 cells. Untransduced primary NK cells cultured in parallel were used
as a control. CAR NK cells were generated by transduction of primary NK cells with huCAR19-LV or huCAR19.CXCR4-LV particles at an MOI of 1–5. (A) Flow
cytometry-based killing assay. After determination of huCAR19 expression, CAR NK cells as well as untransduced primary NK cells were mixed with CFSE-labeled
Nalm-6 cells in different effector-to-target (E:T) ratios as indicated. The percentage of dead target cells were identified as double positive cells for CFSE and viability
dye by flow cytometry. Mean values, SDs, and significance are shown. n = 7 with technical replicates. Unpaired t test was performed to determine significance
comparing CAR NK cells (∗for huCAR19.NK cells; +for huCAR19.CXCR4 NK cells) versus untransduced samples. ++p < 0.005; ∗∗∗p < 0.001; and
∗∗∗∗, ++++p < 0.0001. (B,C) Degranulation (B) and IFNγ secretion assay (C). Transduced as well as untransduced primary NK cells were mixed with Nalm-6 cells
at an E:T ratio of 1. In the first hour of coculture FITC conjugated anti-CD107a antibody was added. After 4 h, cells and supernatant were collected. Harvested cells
were used to determine CD107a expression by flow cytometry (B). IFNγ secretion was determined in the supernatant by ELISA (C). Bar diagrams show individual
results as well as mean values, SDs, and significance. n = 5 with technical replicates. ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001; ns, non-significant by unpaired t test.
of migrated cells was nearly twofold enhanced compared to
the huCAR19 NK cells and even threefold compared to the
untransduced cells (Figure 4A). Untransduced NK cells exhibited
a slight tendency to migrate through the transwell even in the
absence of SDF-1 (Figure 4B).
To prove that the enhanced migration ability of
huCAR19.CXCR4 NK cells is triggered by CXCR4
overexpression, chemotaxis toward SDF-1 was blocked by
treating the NK cells with the antagonist AMD3100 for
2 h prior to the migration assay. The number of migrated
huCAR19.CXCR4 NK cells after treatment with AMD3100
decreased dramatically from ∼13,100 to ∼2300 cells (roughly a
sixfold decline), which is close to the baseline level defined by
the amount of untransduced NK cells migrated in the absence
of SDF-1 (∼1500; Figure 4B). Notably, the moderate migration
ability of huCAR19-LV transduced or untransduced cells was
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FIGURE 4 | Chemotaxis of NK cells is enhanced by CXCR4 overexpression. The migratory potential of genetically modified NK cells was evaluated in a migration
assay using transwell plates. CAR NK cells were generated by transduction of primary NK cells with huCAR19-LV or huCAR19.CXCR4-LV particles. Untransduced
primary NK cells cultured in parallel were used as a control. (A) Genetically modified or untransduced NK cells were placed in the upper chamber of the transwell
plate and analyzed for their potential to migrate toward a lower chamber containing SDF-1 (CXCL12). The number of migrated NK cells was counted by flow
cytometry. n = 4 with technical replicates. (B) Migration potential of NK cells was blocked by the CXCR4 antagonist AMD3100. Untreated or AMD3100 preincubated
NK cells were placed in the upper chamber of the transwell plate and analyzed for their potential to migrate in the presence or absence of SDF-1. The number of
migrated NK cells was counted by flow cytometry. The experiment was done in technical replicates. (C) A coculture assay was performed (in a 1:1 ratio) with
migrated NK cells post chemotaxis to determine their cytotoxic potential. Specific target cell lysis was determined by decrease in the percentage of living
CD19-positive cells analyzed by flow cytometry. n = 3. The experiment was done in technical replicates. Bar diagram show mean value, SD, and significance.
**p < 0.005; ***p < 0.001; ns, non-significant by unpaired t test. (D) The migration potential of CSFE-labeled NK cells with or without AMD3100 pretreatment toward
BMSCs plated in the lower wells. Representative fluorescent microscopic pictures of migrated, CFSE-labeled NK cells (right) as well as quantitative data by flow
cytometry (left) is shown. Bar diagram shows individual results as well as mean values and standard deviation. The experiment was carried out once with purified NK
cells from two different donors.
reduced near to baseline levels in the presence of AMD3100 as
well (Figure 4B).
To investigate the target-specific lysis potency of transduced
cells after migration, a killing assay was performed following
an independent transwell migration assay using SDF-1 as
the chemotactic factor. In comparison to untransduced cells,
significantly higher target cell lysis was observed in coculture with
CD19+ Nalm-6 cells in a 1:1 ratio by both types of huCAR19 NK
cells (Figure 4C).
To further mimic the bone marrow environment and NK
cell homing, another migration assay was performed, seeding
BMSCs in the lower wells of the transwell plate instead of
SDF-1. To discriminate migrated NK cells from BMSCs, NK
cells were labeled with CFSE before loading into the upper
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chamber of the transwell. Fluorescent microscopic imaging and
quantification by flow cytometry of migrated cells revealed
that the presence of BMSCs is sufficient to induce enhanced
chemotaxis of CXCR4-augmented NK cells (more than fourfold
compared to huCAR19 NK cells and untransduced cells), which
can be abrogated by AMD3100 (Figure 4D and Supplementary
Figure S6A). Notably, the addition of recombinant SDF-1 to
BMSCs in the lower wells increased the total number of migrated
huCAR19.CXCR4 NK cells for at least one donor, but also
elevated the levels of migrated huCAR19 NK and untransduced
NK cells, which were all close to the background upon AMD3100
treatment (Supplementary Figures S6B,C).
Taken together, these observations demonstrate that
huCAR19 NK cells augmented with CXCR4 are able to
eradicate CD19+ tumor cells in a CAR-dependent manner,
have significantly enhanced migration ability, and retain their
functional activity post-migration.
DISCUSSION
Translation of CAR NK cell therapy into clinics is ongoing at a
slow pace behind adoptive CAR T-cell therapy owing to some
drawbacks regarding not only purification and expansion, but
also efficient delivery of transgenes into NK cells and migration
capacity (28, 29).
Natural killer cell lines can overcome these limitations, but
they have other obstacles with regard to clinical applicability.
Although, for basic research, several NK cell lines exist, the
only clinically applicable cell line is NK-92. CAR-expressing
NK-92 cells are currently under clinical evaluation, but clinical
efficacy has to be awaited (30, 31). One major disadvantage of
CAR NK-92 cells is their lymphoma origin, requiring irradiation
before infusion, limiting their persistence, proliferation, and
cytotoxic potential (7). This presents a challenge, especially when
attempting to treat rapidly progressing cancers, such as AML.
Therefore, CAR NK cells of primary origin are favored over
CAR NK-92 cells for certain indications. In the current study,
we demonstrate for the first time a highly efficient generation
of CAR NK cells derived from peripheral blood encoding fully
human CD19-specific CAR augmented by human CXCR4 with
potent antitumor activity and migration capability. Genetic
modification of primary NK cells was achieved by transduction
with third-generation LV particles pseudotyped with VSV-G
using polybrene as an enhancer. Interestingly, the transduction
of primary NK cells was as efficient as that of the NK cell lines.
This quite surprising CAR gene delivery to primary NK cells was
not only reproducible in repeated experiments, but it was also
stable for at least 2 weeks post-transduction. In addition, cell
viability, proliferation capacity, and phenotype were not affected
by polybrene or the transgene. This is especially important for
the generation of a sufficient number of CAR NK cells for
immunotherapy. Further, a high NK cell purity was achieved
upon isolation, which is important to avoid T-cell mediated
GvHD upon infusion of allogeneic NK cell products (2).
The choice of transduction enhancer and viral envelope
protein can tremendously influence transduction efficiencies
(26). Direct comparison of Retronectin, Vectofusin-1, and
polybrene revealed that Vectofusin-1 and polybrene are beneficial
for the transduction of primary NK cells using VSV-G
peusdotyped LV particles and clearly outperform Retronectin.
Polybrene is also a well-known transduction enhancer in the field
of NK cells. High transduction efficiencies can be reached for
NK cell lines, but for primary NK cells, gene transfer rates of
only 8–55% were reported depending on the viral vector and cell
source used (32–34). In our study, on average, more than 80% of
gene modified NK cells could be reached. Notably, in contrast to
Boissel and colleagues (33), we did not observe a negative effect of
polybrene on NK cell viability or proliferation. Similar high gene
transfer rates to primary NK cells were reached using Vecotfusin-
1 as an enhancer, which might even be increased when using
a different viral envelope. For Vectofusin-1, it was recently
demonstrated that transgene delivery to primary NK cells can
be improved by pseudotyping LVs with the envelope protein
from endogenous feline virus (RD114) or baboon endogenous
retrovirus (BaEV) instead of VSV-G (5, 6). In the field of CAR
T-cells gamma-retroviral vectors or VSV-G pseudotyped LVs are
most commonly used for their generation. Therefore, clinical
translation of CAR NK cells will benefit from the use of an already
approved viral vector, highlighting the value of the demonstrated
high transduction efficiency of primary NK cells in the current
study with VSV-G pseudotyped LVs (33).
A clinical grade lentiviral expression backbone harboring
a fully human CD19-specific CAR construct with or without
additional human CXCR4 gene was used to generate huCAR19
and huCAR19.CXCR4 NK cells, respectively. Both CAR NK cells
showed potent and specific antitumor activity on CD19-positive
patient-derived primary tumor cell lines of various origin,
including peripheral blood– or bone marrow–derived B-cell
precursor leukemia cells from ALL or chronic myeloid leukemia
patients and peripheral blood–derived B-cell lymphoma cells
from a patient with non-Hodgkins lymphoma. In addition, upon
antigen stimulation, robust INF-γ secretion and upregulation of
the degranulation marker CD107a were induced. These results
demonstrate that the fully human CD19 CAR construct not
only shows strong antitumor activity in T-cells (11), but is
also very effective upon introduction to NK cells in terms of
cytokine secretion and tumor cell lysis. Notably, the types of
proinflammatory cytokines secreted by NK cells differ from those
produced by T cells. Ex vivo expanded primary human NK cells
are known to mainly secrete IFN-γ and GM-CSF upon activation,
which are relatively safer than the proinflammatory cytokines
produced by T-cells, including TNF-α and IL-6 (35, 36). Secretion
of IL-6, IL-1, and TNF-α by CAR T-cells is associated with the
development of CRS, a common and severe side effect of CAR T
cell therapy. In contrast to CAR T-cells, activated CD19-specific
primary CAR NK cells, CAR NK92 cells, or CAR CIK cells were
shown by us and others to secrete high levels of IFN-γ and/or
GM-CSF but only moderate levels of TNF-α, and production of
IL-6 was not observed (37–39). A recent report of a clinical trial
did reveal that, among 11 patients with relapsed or refractory
CD19-positive malignancies, the majority had a clinical response
to treatment with primary CD19-specific CAR NK cells without
the development of major toxic effects, including CRS (40),
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supporting the hypothesis that CAR NK cells might be a safer
alternative to CAR T-cells.
Concerning the limited migratory potency of NK cells to
malignant cells residing in bone marrow niches or other tumor
sites, promoting NK cell chemotaxis via chemokine receptor
upregulation has been considered before. Primary NK cells
engineered to express the chemokine receptor CCR7 or CXCR2
were demonstrated to have an improved migratory ability
toward their respective ligands (41, 42). In an NK cell line,
even the combination of CAR and CXCR4 were evaluated,
showing that YT2 cells expressing EGFRvIII-CAR and CXCR4
migrate to and specifically kill SDF-1-secreting glioblastoma
cells (43). For T-cells, CXCR4 overexpression enhanced their
bone marrow migration resulting in local engraftment (44).
For NK cells, the power of CXCR4 expression was recently
demonstrated by exploring the CXCR4 gain of function mutation
present in WHIM (warts, hypogammaglobulinemia, infections,
and myelokathexis) syndrome, resulting in an increased NK
cell migration toward bone marrow (19, 45). In our study, we
could show efficient overexpression of native human CXCR4 on
primary CAR NK cells upon genetic engineering. These TRACKs
displayed not only strong and specific antitumor activity, but also
enhanced chemotaxis toward recombinant SDF-1 and BMSCs.
This boosted migratory potential might facilitate an improved
clearing of CD19 positive tumor cells residing in the bone
marrow in vivo, which has to be explored in future work. In
conclusion, this work demonstrates that TRACKs could be an
important player for NK cell–based adoptive cell therapy and
should be further investigated for their translation to clinics.
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